Roivant mosliciguat hits Phase 2 goals, cuts lung pressure 56% — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mosliciguat achieved a statistically significant 56% reduction versus placebo in pulmonary vascular resistance — the Phase 2 trial's primary endpoint — over 16 weeks
- Roivant's drug improved six-minute walk distance by 35 meters on a placebo-adjusted basis, a key secondary endpoint that also reached statistical significance
- Mosliciguat cut NT-proBNP, a blood-based marker of heart failure, by 53% placebo-adjusted, hitting the other key secondary endpoint
- Roivant is positioning mosliciguat as a potential second blockbuster medicine, with the positive mid-stage results strengthening the biotech's financial outlook
- Mosliciguat is being developed as a new mechanism for pulmonary hypertension, a serious lung disease that damages the artery connecting the right side of the heart to the lungs
Why it matters: Roivant gains a credible Phase 2 win in pulmonary hypertension — a disease area where new mechanisms are scarce — and the three statistically significant endpoints (56% PVR cut, 35-meter walk gain, 53% NT-proBNP drop) give the company a differentiated asset that could become a second revenue driver beyond its existing blockbuster.
Ask SkimNews
